THIS WEBSITE USES COOKIES

We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Skip to content

News

New article published on Immunomodulatory Properties of Amniotic Membrane Derivatives and Their Potential in Regenerative Medicine

June 12, 2020 No Comments

The VANGUARD coordinator, Ekaterine Berishvili together with Charles-Henri Wassmer have recently published a new article in Current Diabetes Reports on the Immunomodulatory Properties of Amniotic Membrane Derivatives and Their Potential in Regenerative Medicine.

Purpose of Review

During the last decades, the field of regenerative medicine has been rapidly evolving. Major progress has been made in the development of biological substitutes applying the principles of cell transplantation, material science, and bioengineering.

Recent Findings

Among other sources, amniotic-derived products have been used for decades in various fields of medicine as a biomaterial for the wound care and tissue replacement. Moreover, human amniotic epithelial and mesenchymal cells have been intensively studied for their immunomodulatory capacities.

Summary

Amniotic cells possess two major characteristics that have already been widely exploited. The first is their ability to modulate and suppress the innate and adaptive immunities, making them a true asset for chronic inflammatory disorders and for the induction of tolerance in transplantation models. The second is their multilineage differentiation capacity, offering a source of cells for tissue engineering. The latter combined with the use of amniotic membrane as a scaffold offers all components necessary to create an optimal environment for cell and tissue regeneration. This review summarizes beneficial properties of hAM and its derivatives and discusses their potential in regenerative medicine.

Read the full article online: https://link.springer.com/article/10.1007/s11892-020-01316-w

New research on a promising treatment against type 1 diabetes funded by the European Commission

February 18, 2020 No Comments

More than 40 million individuals worldwide are affected by type 1 diabetes, which is the most common chronic disease in children and adolescents. Today’s primary treatment for diabetes is insulin therapy, which requires multiple injections every day to control a person’s blood sugar levels. This can potentially lead to chronic complications such as kidney-related issues (nephropathy), visual impairments (retinopathy) and ischemic heart disease. Beta-cell replacement, done either by pancreas or islet transplantation, is a valid alternative to daily injections, as it restores the possibility to control blood sugar levels (glucose). However, pancreas or islet transplantations rely on organ donors and require lifelong anti-rejection medication to avoid the rejection of the transplanted organ or cells. The process is also associated with complications and is currently only offered to a limited number of patients with severe forms of the disease.
Within the framework of a European funded H2020 project, VANGUARD aims to develop a cure for type 1 diabetes available to a larger group of patients. The VANGUARD project will use advanced tissue engineering techniques to generate a bioartificial pancreas, with the aim to propose a novel cell-based treatment to type 1 diabetes that overcomes the limitations inherent to current therapies. Working on this innovative solution is a multidisciplinary team of researchers from Switzerland, Italy, France, Germany and The Netherlands, led by Dr Ekaterine Berishvili from the University of Geneva, Department of Surgery. According to Dr. Berishvili “the VANGUARD multidisciplinary team will bring regenerative medicine for type I diabetes from bench to bedside”. In total, the project brings together outstanding expertise from six academic institutions with leading scientists in bioengineering, transplantation, gene therapy, immunology and ethics, two SMEs and an NGO.

VANGUARD’s bioartificial pancreas has the potential to improve the success rate of beta-cell replacement therapies with exceptional advantages in terms of efficacy and safety. The treatment of a large number of patients with type 1 diabetes could dramatically reduce the financial burden of the disease, mostly associated with the healthcare costs of chronic secondary complications of diabetes.

The VANGUARD project officially started and had its kick-off last month in January 2020, in conjunction with the annual symposium of the European Pancreas and Islet Transplant Association. Representatives from the nine project partners discussed the start of the research activities and the path towards what has the potential to be a real breakthrough towards a cure for type 1 diabetes.

Scientific contact

University of Geneva
Dr Ekaterine Berishvili
Researcher and Coordinator of the VANGUARD project
Department of Surgery
Faculty of Medicine
project@vanguard-project.eu

About VANGUARD

The VANGUARD project is funded by the European research and innovation program Horizon 2020 (project number 874700), under the Health program. It is a five-year project that officially started in January 2020 and will end in December 2024. It involves nine project partners from seven European countries and has a budget of € 6.8 million.
www.vanguard-project.eu

VANGUARD Press Release 18 February 2020 PDFDownload

VANGUARD partners meet for the first time

February 6, 2020 No Comments

Representatives from the eight VANGUARD partners travelled from across Europe to Igls in Austria to officially kick-off the project. The meeting took place on the 25th January 2020 and offered all partners the opportunity to get to know each other and their roles within the VANGUARD project in more detail.

VANGUARD selected for Horizon 2020 funding

January 21, 2020 No Comments

Our VANGUARD proposal to develop a new bioartificial pancreas to cure type 1 diabetes has been selected for funding by the European Commission. Under the call SC1-BHC-07-2019 Regenerative medicine: from new insights to new applications, VANGUARD has been selected as one of twelve projects to be funded.

The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin-producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel.

The consortium consists of 6 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. We look forward to the project start on 1st January 2020 and to start collaborating together to provide a model for the development of a bioartificial pancreas.